Allogene Therapeutics Competitors and Similar CompaniesClear all
Allogene Therapeutics's competitors and similar companies include Bellicum Pharmaceuticals, Plus Therapeutics, Gilead Sciences, Novartis, Amgen and Cellectis.
 Allogene Therapeutics Allogene Therapeutics is a clinical-stage biotechnology company developing allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer. |  Bellicum Pharmaceuticals Bellicum Pharmaceuticals is a biopharmaceutical company focused on discovering and developing cellular immunotherapies. |  Plus Therapeutics Plus Therapeutics is a pharmaceutical company focused on the development of treatments for patients battling cancer and other life-threatening diseases. |  Gilead Sciences Gilead Sciences is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of medicines. |  Novartis Novartis is a company that researches, develops, manufactures, and markets healthcare products. |  Amgen Amgen (formerly known as Applied Molecular Genetics) is a biotechnology company that discovers, develops, manufactures, and delivers human therapeutics. |  Cellectis Cellectis is a clinical-stage biopharmaceutical company that develops cell and gene therapies. | |
Founding Date | Founding Date 2018 | Founding Date 2004 | Founding Date 1996 | Founding Date 1987 | Founding Date 1996 | Founding Date 1980 | Founding Date 1999 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | |||||||
Locations | Locations South San Francisco, US HQ | Locations Houston, US HQ Houston, US Houston, US South San Francisco, US | Locations Austin, US HQ San Antonio, US | Locations Foster City, US HQ Buenos Aires, AR Melbourne, AU Wien, AT Machelen, BE São Paulo, BR Edmonton, CA see more | Locations Basel, CH HQ Tirana, AL Buenos Aires, AR Macquarie Park, AU Kundl, AT Unterlangkampfen, AT Wien, AT see more | Locations Thousand Oaks, US HQ Hydra, DZ Vicente López, AR Sydney, AU Wien, AT Diegem, BE Santo Amaro, BR see more | Locations Paris, FR HQ New York, US Raleigh, US |
Employees | Employees 2263% decrease | Employees 1386% increase | Employees 1721% increase | Employees 18,0006% increase | Employees 75,883 | Employees 25,200 | Employees 216 |
Valuation ($) | Valuation ($) 585.5 m | Valuation ($) 778.3 k | Valuation ($) 8 m | Valuation ($) 110.5 b | Valuation ($) N/A | Valuation ($) 170.4 b | Valuation ($) 189.4 m |
Financial | |||||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $1.5m (FY, 2022) | Revenue (est.) $5.2m (FY, 2025) | Revenue (est.) $29.4b (FY, 2025) | Revenue (est.) $56.7b (FY, 2025) | Revenue (est.) $36.8b (FY, 2025) | Revenue (est.) $72.9m (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods $6.2b (FY, 2025) | Cost of goods $8.4b (FY, 2025) | Cost of goods $12b (FY, 2025) | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit N/A | Gross profit $23.2b (FY, 2025) | Gross profit $49.8b (FY, 2025) | Gross profit $24.7b (FY, 2025) | Gross profit $80.2m (FY, 2025) |
Net income | Net income ($190.9m) (FY, 2025) | Net income ($25m) (FY, 2022) | Net income ($22.4m) (FY, 2025) | Net income $8.5b (FY, 2025) | Net income $14b (FY, 2025) | Net income $7.7b (FY, 2025) | Net income ($67.6m) (FY, 2025) |
Operating ⚠ | |||||||
Countries | Countries N/A | Countries N/A | Countries N/A | Countries 35 (FY, 2021) | Countries N/A | Countries 100 (FY, 2020) | Countries N/A |
Phase I Trials Products | Phase I Trials Products 4 (FY, 2019) | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products 20 (FY, 2020) | Phase I Trials Products N/A |
Phase III Trials Products | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products 9 (FY, 2021) | Phase III Trials Products 44 (FY, 2022) | Phase III Trials Products 11 (FY, 2020) | Phase III Trials Products N/A |
Phase III Trials Products (Oncology) | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) 4 (FY, 2021) | Phase III Trials Products (Oncology) 27 (FY, 2021) | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A |
Funding | |||||||
Total funding raised | Total funding raised $ 532m | Total funding raised N/A | Total funding raised $ 71.9m | Total funding raised N/A | Total funding raised $ 6.5m | Total funding raised N/A | Total funding raised $ 3.2m |
For sources of this data, please see the company profile
View Company Profiles
Bellicum Pharmaceuticals
HQ
Houston, US
Employees
13
Bellicum Pharmaceuticals is a biopharmaceutical company focused on discovering and developing cellular immunotherapies.
View companyPlus Therapeutics
HQ
Austin, US
Employees
17↑ 21% increase
Plus Therapeutics is a pharmaceutical company focused on the development of treatments for patients battling cancer and other life-threatening diseases.
View companyGilead Sciences
HQ
Foster City, US
Employees
18,000↑ 6% increase
Gilead Sciences is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of medicines.
View companyNovartis
HQ
Basel, CH
Employees
75,883
Novartis is a company that researches, develops, manufactures, and markets healthcare products.
View company